CoChat
Sign Up
Cited by 92

SOCS proteins in regulation of receptor tyrosine kinase signaling

Kazi, Julhash U., Kabir, Nuzhat N., Flores-Morales, Amilcar, Rönnstrand, Lars·2014·Cellular and Molecular Life Sciences
DOI 10.1007/s00018-014-1619-y
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00018-014-1619-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 104

  1. [1]Kazi JU, Kabir NN, Soh JW. Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. Gene. 2008;410:147–153. doi: 10.1016/j.gene.2007.12.003. [DOI] [PubMed] [Google Scholar] · DOI
  2. [2]Kabir NN, Kazi JU. Comparative analysis of human and bovine protein kinases reveals unique relationship and functional diversity. Genet Mol Biol. 2011;34:587–591. doi: 10.1590/S1415-47572011005000035. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  3. [3]Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134. doi: 10.1016/j.cell.2010.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  4. [4]Kazi JU, Vaapil M, Agarwal S, Bracco E, Påhlman S, Rönnstrand L. The tyrosine kinase CSK associates with FLT3 and c-Kit receptors and regulates downstream signaling. Cell Signal. 2013;25:1852–1860. doi: 10.1016/j.cellsig.2013.05.016. [DOI] [PubMed] [Google Scholar] · DOI
  5. [5]Kazi JU, Rönnstrand L. FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia. Mol Oncol. 2013;7:402–418. doi: 10.1016/j.molonc.2012.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  6. [6]Lin DC, Yin T, Koren-Michowitz M, et al. Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3. Blood. 2012;120:3310–3317. doi: 10.1182/blood-2011-10-388611. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  7. [7]Kazi JU, Rönnstrand L. Src-Like adaptor protein (SLAP) binds to the receptor tyrosine kinase Flt3 and modulates receptor stability and downstream signaling. PLoS One. 2012;7:e53509. doi: 10.1371/journal.pone.0053509. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  8. [8]Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92:1619–1649. doi: 10.1152/physrev.00046.2011. [DOI] [PubMed] [Google Scholar] · DOI
  9. [9]Masson K, Rönnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal. 2009;21:1717–1726. doi: 10.1016/j.cellsig.2009.06.002. [DOI] [PubMed] [Google Scholar] · DOI
  10. [10]Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995;14:2816–2826. doi: 10.1002/j.1460-2075.1995.tb07281.x. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  11. [11]Masuhara M, Sakamoto H, Matsumoto A, et al. Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun. 1997;239:439–446. doi: 10.1006/bbrc.1997.7484. [DOI] [PubMed] [Google Scholar] · DOI
  12. [12]Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 1997;387:921–924. doi: 10.1038/43213. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  13. [13]Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–921. doi: 10.1038/43206. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  14. [14]Hilton DJ, Richardson RT, Alexander WS, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA. 1998;95:114–119. doi: 10.1073/pnas.95.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  15. [15]Kile BT, Alexander WS. The suppressors of cytokine signalling (SOCS) Cell Mol Life Sci. 2001;58:1627–1635. doi: 10.1007/PL00000801. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  16. [16]Kazi JU, Rönnstrand L. Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling. Mol Oncol. 2013;7:693–703. doi: 10.1016/j.molonc.2013.02.020. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  17. [17]Kazi JU, Sun J, Phung B, Zadjali F, Flores-Morales A, Rönnstrand L. Suppressor of cytokine signaling 6 (SOCS6) negatively regulates Flt3 signal transduction through direct binding to phosphorylated tyrosines 591 and 919 of Flt3. J Biol Chem. 2012;287:36509–36517. doi: 10.1074/jbc.M112.376111. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  18. [18]Bayle J, Letard S, Frank R, Dubreuil P, De Sepulveda P. Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem. 2004;279:12249–12259. doi: 10.1074/jbc.M313381200. [DOI] [PubMed] [Google Scholar] · DOI
  19. [19]Kawazoe Y, Naka T, Fujimoto M, et al. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med. 2001;193:263–269. doi: 10.1084/jem.193.2.263. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  20. [20]Jamieson E, Chong MM, Steinberg GR, et al. Socs1 deficiency enhances hepatic insulin signaling. J Biol Chem. 2005;280:31516–31521. doi: 10.1074/jbc.M502163200. [DOI] [PubMed] [Google Scholar] · DOI
  21. [21]Wiejak J, Dunlop J, Gao S, Borland G, Yarwood SJ. Extracellular signal-regulated kinase mitogen-activated protein kinase-dependent SOCS-3 gene induction requires c-Jun, signal transducer and activator of transcription 3, and specificity protein 3 transcription factors. Mol Pharmacol. 2012;81:657–668. doi: 10.1124/mol.111.076976. [DOI] [PubMed] [Google Scholar] · DOI
  22. [22]Iglesias-Gato D, Chuan YC, Wikström P, et al. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis. 2014;35:24–33. doi: 10.1093/carcin/bgt304. [DOI] [PubMed] [Google Scholar] · DOI
  23. [23]Okochi O, Hibi K, Sakai M, et al. Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis. Clin Cancer Res. 2003;9:5295–5298. [PubMed] [Google Scholar]
  24. [24]He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA. 2003;100:14133–14138. doi: 10.1073/pnas.2232790100. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  25. [25]De Sepulveda P, Okkenhaug K, Rose JL, Hawley RG, Dubreuil P, Rottapel R. Socs1 binds to multiple signalling proteins and suppresses steel factor-dependent proliferation. EMBO J. 1999;18:904–915. doi: 10.1093/emboj/18.4.904. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  26. [26]Reddy PN, Sargin B, Choudhary C, et al. SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. Blood. 2012;120:1691–1702. doi: 10.1182/blood-2010-08-301416. [DOI] [PubMed] [Google Scholar] · DOI
  27. [27]Rottapel R, Ilangumaran S, Neale C, et al. The tumor suppressor activity of SOCS-1. Oncogene. 2002;21:4351–4362. doi: 10.1038/sj.onc.1205537. [DOI] [PubMed] [Google Scholar] · DOI
  28. [29]Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24:5434–5446. doi: 10.1128/MCB.24.12.5434-5446.2004. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  29. [30]Bourette RP, De Sepulveda P, Arnaud S, Dubreuil P, Rottapel R, Mouchiroud G. Suppressor of cytokine signaling 1 interacts with the macrophage colony-stimulating factor receptor and negatively regulates its proliferation signal. J Biol Chem. 2001;276:22133–22139. doi: 10.1074/jbc.M101878200. [DOI] [PubMed] [Google Scholar] · DOI
  30. [31]Yu W, Chen J, Xiong Y, et al. CSF-1 receptor structure/function in MacCsf1r-/- macrophages: regulation of proliferation, differentiation, and morphology. J Leukoc Biol. 2008;84:852–863. doi: 10.1189/jlb.0308171. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  31. [32]Gui Y, Yeganeh M, Ramanathan S, et al. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J Hepatol. 2011;55:1300–1308. doi: 10.1016/j.jhep.2011.03.027. [DOI] [PubMed] [Google Scholar] · DOI
  32. [33]Hafizi S, Alindri F, Karlsson R, Dahlback B. Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1 domain-containing protein with homology to tensin. Biochem Biophys Res Commun. 2002;299:793–800. doi: 10.1016/S0006-291X(02)02718-3. [DOI] [PubMed] [Google Scholar] · DOI
  33. [34]Dey BR, Spence SL, Nissley P, Furlanetto RW. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem. 1998;273:24095–24101. doi: 10.1074/jbc.273.37.24095. [DOI] [PubMed] [Google Scholar] · DOI
  34. [35]Xia L, Wang L, Chung AS, et al. Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem. 2002;277:30716–30723. doi: 10.1074/jbc.M202823200. [DOI] [PubMed] [Google Scholar] · DOI
  35. [36]Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci. 2006;119:380–387. doi: 10.1242/jcs.02740. [DOI] [PubMed] [Google Scholar] · DOI
  36. [37]Choudhary C, Brandts C, Schwable J, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood. 2007;110:370–374. doi: 10.1182/blood-2006-05-024018. [DOI] [PubMed] [Google Scholar] · DOI
  37. [38]Gui Y, Yeganeh M, Cepero-Donates Y, Ramanathan S, Saucier C, Ilangumaran S. Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma. Curr Pharm Des. 2013;19:1–12. doi: 10.2174/13816128113199990597. [DOI] [PubMed] [Google Scholar] · DOI
  38. [39]Kazi JU, Agarwal S, Sun J, Bracco E, Rönnstrand L. Src-like adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling. J Cell Sci. 2014;127:653–662. doi: 10.1242/jcs.140590. [DOI] [PubMed] [Google Scholar] · DOI
  39. [40]Gulli LF, Palmer KC, Chen YQ, Reddy KB. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ. 1996;7:173–178. [PubMed] [Google Scholar]
  40. [41]Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biol Toxicol. 2012;28:201–212. doi: 10.1007/s10565-012-9216-z. [DOI] [PubMed] [Google Scholar] · DOI
  41. [42]Greenhalgh CJ, Rico-Bautista E, Lorentzon M, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest. 2005;115:397–406. doi: 10.1172/JCI200522710. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  42. [43]Vesterlund M, Zadjali F, Persson T, et al. The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. PLoS One. 2011;6:e25358. doi: 10.1371/journal.pone.0025358. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  43. [44]Lopaczynski W. Differential regulation of signaling pathways for insulin and insulin-like growth factor I. Acta Biochim Pol. 1999;46:51–60. [PubMed] [Google Scholar]
  44. [45]Kazi JU, Kabir NN, Rönnstrand L. Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia. Med Oncol. 2013;30:575. doi: 10.1007/s12032-013-0757-7. [DOI] [PubMed] [Google Scholar] · DOI
  45. [46]Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol. 2003;5:461–466. doi: 10.1038/ncb983. [DOI] [PubMed] [Google Scholar] · DOI
  46. [47]Farabegoli F, Ceccarelli C, Santini D, Taffurelli M. Suppressor of cytokine signalling 2 (SOCS-2) expression in breast carcinoma. J Clin Pathol. 2005;58:1046–1050. doi: 10.1136/jcp.2004.024919. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  47. [48]Goldshmit Y, Walters CE, Scott HJ, Greenhalgh CJ, Turnley AM. SOCS2 induces neurite outgrowth by regulation of epidermal growth factor receptor activation. J Biol Chem. 2004;279:16349–16355. doi: 10.1074/jbc.M312873200. [DOI] [PubMed] [Google Scholar] · DOI
  48. [49]Roberts AW, Robb L, Rakar S, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA. 2001;98:9324–9329. doi: 10.1073/pnas.161271798. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  49. [51]Jo D, Liu D, Yao S, Collins RD, Hawiger J. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat Med. 2005;11:892–898. doi: 10.1038/nm1269. [DOI] [PubMed] [Google Scholar] · DOI
  50. [52]Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem. 2000;275:15985–15991. doi: 10.1074/jbc.275.21.15985. [DOI] [PubMed] [Google Scholar] · DOI
  51. [54]Dey BR, Furlanetto RW, Nissley P. Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun. 2000;278:38–43. doi: 10.1006/bbrc.2000.3762. [DOI] [PubMed] [Google Scholar] · DOI
  52. [55]Zolotnik IA, Figueroa TY, Yaspelkis BB., 3rd Insulin receptor and IRS-1 co-immunoprecipitation with SOCS-3, and IKKalpha/beta phosphorylation are increased in obese Zucker rat skeletal muscle. Life Sci. 2012;91:816–822. doi: 10.1016/j.lfs.2012.08.038. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  53. [56]Peraldi P, Filloux C, Emanuelli B, Hilton DJ, Van Obberghen E. Insulin induces suppressor of cytokine signaling-3 tyrosine phosphorylation through janus-activated kinase. J Biol Chem. 2001;276:24614–24620. doi: 10.1074/jbc.M102209200. [DOI] [PubMed] [Google Scholar] · DOI
  54. [57]Sundaram K, Senn J, Reddy SV. SOCS-1/3 participation in FGF-2 signaling to modulate RANK ligand expression in Paget’s disease of bone. J Cell Biochem. 2013;114:2032–2038. doi: 10.1002/jcb.24554. [DOI] [PubMed] [Google Scholar] · DOI
  55. [58]Cacalano NA, Sanden D, Johnston JA. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol. 2001;3:460–465. doi: 10.1038/35074525. [DOI] [PubMed] [Google Scholar] · DOI
  56. [59]Kario E, Marmor MD, Adamsky K, et al. Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem. 2005;280:7038–7048. doi: 10.1074/jbc.M408575200. [DOI] [PubMed] [Google Scholar] · DOI
  57. [60]Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S. Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure. 2007;15:1493–1504. doi: 10.1016/j.str.2007.09.016. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  58. [61]Nicholson SE, Metcalf D, Sprigg NS, et al. Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci USA. 2005;102:2328–2333. doi: 10.1073/pnas.0409675102. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  59. [62]Linossi EM, Chandrashekaran IR, Kolesnik TB, et al. Suppressor of cytokine signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1. PLoS One. 2013;8:e70536. doi: 10.1371/journal.pone.0070536. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  60. [63]Lai RH, Hsiao YW, Wang MJ, et al. SOCS6, down-regulated in gastric cancer, inhibits cell proliferation and colony formation. Cancer Lett. 2010;288:75–85. doi: 10.1016/j.canlet.2009.06.025. [DOI] [PubMed] [Google Scholar] · DOI
  61. [64]Sriram KB, Larsen JE, Savarimuthu Francis SM, et al. Array-comparative genomic hybridization reveals loss of SOCS6 is associated with poor prognosis in primary lung squamous cell carcinoma. PLoS One. 2012;7:e30398. doi: 10.1371/journal.pone.0030398. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  62. [65]Krebs DL, Uren RT, Metcalf D, et al. SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol. 2002;22:4567–4578. doi: 10.1128/MCB.22.13.4567-4578.2002. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  63. [66]Li L, Grønning LM, Anderson PO, et al. Insulin induces SOCS-6 expression and its binding to the p85 monomer of phosphoinositide 3-kinase, resulting in improvement in glucose metabolism. J Biol Chem. 2004;279:34107–34114. doi: 10.1074/jbc.M312672200. [DOI] [PubMed] [Google Scholar] · DOI
  64. [67]Mooney RA, Senn J, Cameron S, et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem. 2001;276:25889–25893. doi: 10.1074/jbc.M010579200. [DOI] [PubMed] [Google Scholar] · DOI
  65. [68]Hwang MN, Ha TH, Park J, et al. Increased SOCS6 stability with PMA requires its N-terminal region and the Erk pathway via Pkcdelta activation. Biochem Biophys Res Commun. 2007;354:184–189. doi: 10.1016/j.bbrc.2006.12.175. [DOI] [PubMed] [Google Scholar] · DOI
  66. [69]Zadjali F, Pike AC, Vesterlund M, et al. Structural basis for c-KIT inhibition by the suppressor of cytokine signaling 6 (SOCS6) ubiquitin ligase. J Biol Chem. 2011;286:480–490. doi: 10.1074/jbc.M110.173526. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  67. [70]Sitko JC, Guevara CI, Cacalano NA. Tyrosine-phosphorylated SOCS3 interacts with the Nck and Crk-L adapter proteins and regulates Nck activation. J Biol Chem. 2004;279:37662–37669. doi: 10.1074/jbc.M404007200. [DOI] [PubMed] [Google Scholar] · DOI
  68. [71]Matuoka K, Miki H, Takahashi K, Takenawa T. A novel ligand for an SH3 domain of the adaptor protein Nck bears an SH2 domain and nuclear signaling motifs. Biochem Biophys Res Commun. 1997;239:488–492. doi: 10.1006/bbrc.1997.7492. [DOI] [PubMed] [Google Scholar] · DOI
  69. [72]Martens N, Wery M, Wang P, et al. The suppressor of cytokine signaling (SOCS)-7 interacts with the actin cytoskeleton through vinexin. Exp Cell Res. 2004;298:239–248. doi: 10.1016/j.yexcr.2004.04.002. [DOI] [PubMed] [Google Scholar] · DOI
  70. [73]Banks AS, Li J, McKeag L, et al. Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest. 2005;115:2462–2471. doi: 10.1172/JCI23853. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  71. [74]Sasi W, Ye L, Jiang WG, Mokbel K, Sharma A. Observations on the effects of suppressor of cytokine signaling 7 (SOCS7) knockdown in breast cancer cells: their in vitro response to Insulin like growth factor I (IGF-I) Clin Transl Oncol. 2013 doi: 10.1007/s12094-013-1107-0. [DOI] [PubMed] [Google Scholar] · DOI
  72. [75]Krejci P, Prochazkova J, Bryja V, et al. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal. 2009;21:151–160. doi: 10.1016/j.cellsig.2008.10.006. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  73. [76]Chen S, Anderson PO, Li L, Sjögren HO, Wang P, Li SL. Functional association of cytokine-induced SH2 protein and protein kinase C in activated T cells. Int Immunol. 2003;15:403–409. doi: 10.1093/intimm/dxg039. [DOI] [PubMed] [Google Scholar] · DOI
  74. [77]Raccurt M, Tam SP, Lau P, et al. Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer. 2003;89:524–532. doi: 10.1038/sj.bjc.6601115. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  75. [78]Sasi W, Jiang WG, Sharma A, Mokbel K. Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer. 2010;10:178. doi: 10.1186/1471-2407-10-178. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  76. [79]Li Z, Metze D, Nashan D, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol. 2004;123:737–745. doi: 10.1111/j.0022-202X.2004.23408.x. [DOI] [PubMed] [Google Scholar] · DOI
  77. [80]Zhang J, Li H, Yu JP, Wang SE, Ren XB. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer. 2012;130:1971–1980. doi: 10.1002/ijc.27318. [DOI] [PubMed] [Google Scholar] · DOI
  78. [82]Hanada T, Kobayashi T, Chinen T, et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med. 2006;203:1391–1397. doi: 10.1084/jem.20060436. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  79. [83]Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679–2684. doi: 10.1038/sj.onc.1209151. [DOI] [PubMed] [Google Scholar] · DOI
  80. [84]Hiwatashi K, Tamiya T, Hasegawa E, et al. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Lett. 2011;308:172–180. doi: 10.1016/j.canlet.2011.04.024. [DOI] [PubMed] [Google Scholar] · DOI
  81. [85]Qiu X, Zheng J, Guo X, et al. Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. Mol Cell Biochem. 2013;378:99–106. doi: 10.1007/s11010-013-1599-5. [DOI] [PubMed] [Google Scholar] · DOI
  82. [86]Zhu JG, Dai QS, Han ZD, et al. Expression of SOCSs in human prostate cancer and their association in prognosis. Mol Cell Biochem. 2013;381:51–59. doi: 10.1007/s11010-013-1687-6. [DOI] [PubMed] [Google Scholar] · DOI
  83. [87]Iglesias-Gato D, Chuan YC, Wikström P, et al. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. Carcinogenesis. 2013 doi: 10.1093/carcin/bgt304. [DOI] [PubMed] [Google Scholar] · DOI
  84. [88]Niwa Y, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene. 2005;24:6406–6417. doi: 10.1038/sj.onc.1208788. [DOI] [PubMed] [Google Scholar] · DOI
  85. [89]Zhang L, Li J, Li L, et al. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. 2014 doi: 10.1093/carcin/bgu017. [DOI] [PubMed] [Google Scholar] · DOI
  86. [90]Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood. 2002;100:2926–2931. doi: 10.1182/blood-2002-01-0073. [DOI] [PubMed] [Google Scholar] · DOI
  87. [91]Suessmuth Y, Elliott J, Percy MJ, et al. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Br J Haematol. 2009;147:450–458. doi: 10.1111/j.1365-2141.2009.07860.x. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  88. [92]Quentmeier H, Geffers R, Jost E, et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia. 2008;22:2169–2175. doi: 10.1038/leu.2008.226. [DOI] [PubMed] [Google Scholar] · DOI
  89. [93]Jost E, ON do, Dahl E, et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia. 2007;21:505–510. doi: 10.1038/sj.leu.2404513. [DOI] [PubMed] [Google Scholar] · DOI
  90. [94]Etienne A, Carbuccia N, Adelaide J, et al. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes. Cancer Genet Cytogenet. 2007;176:80–88. doi: 10.1016/j.cancergencyto.2007.03.009. [DOI] [PubMed] [Google Scholar] · DOI
  91. [95]Fourouclas N, Li J, Gilby DC, et al. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 2008;93:1635–1644. doi: 10.3324/haematol.13043. [DOI] [PubMed] [Google Scholar] · DOI
  92. [96]Haan S, Ferguson P, Sommer U, et al. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem. 2003;278:31972–31979. doi: 10.1074/jbc.M303170200. [DOI] [PubMed] [Google Scholar] · DOI
  93. [97]Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA. 2004;101:10422–10427. doi: 10.1073/pnas.0402511101. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  94. [98]Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res. 2005;33:185–192. doi: 10.1016/j.hepres.2005.09.032. [DOI] [PubMed] [Google Scholar] · DOI
  95. [99]Kato H, Nomura K, Osabe D, et al. Association of single-nucleotide polymorphisms in the suppressor of cytokine signaling 2 (SOCS2) gene with type 2 diabetes in the Japanese. Genomics. 2006;87:446–458. doi: 10.1016/j.ygeno.2005.11.009. [DOI] [PubMed] [Google Scholar] · DOI
  96. [100]Ramos MI, Perez SG, Aarrass S, et al. FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis. Arthritis Res Ther. 2013;15:R209. doi: 10.1186/ar4403. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  97. [101]Madan B, Goh KC, Hart S, et al. SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J Immunol. 2012;189:4123–4134. doi: 10.4049/jimmunol.1200675. [DOI] [PubMed] [Google Scholar] · DOI
  98. [102]Juurikivi A, Sandler C, Lindstedt KA, et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis. 2005;64:1126–1131. doi: 10.1136/ard.2004.029835. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  99. [103]Tsao JT, Kuo CC, Lin SC. The analysis of CIS, SOCS1, SOSC2 and SOCS3 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Clin Exp Med. 2008;8:179–185. doi: 10.1007/s10238-008-0006-0. [DOI] [PubMed] [Google Scholar] · DOI
  100. [104]Chen YH, Hsieh SC, Chen WY, et al. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFbeta1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis. 2011;70:1655–1663. doi: 10.1136/ard.2010.145821. [DOI] [PubMed] [Google Scholar] · DOI
  101. [105]De Souza D, Fabri LJ, Nash A, Hilton DJ, Nicola NA, Baca M. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry. 2002;41:9229–9236. doi: 10.1021/bi0259507. [DOI] [PubMed] [Google Scholar] · DOI
  102. [106]Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014;25:226–242. doi: 10.1016/j.ccr.2014.01.022. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  103. [107]Kabir NN, Kazi JU. Grb10 is a dual regulator of receptor tyrosine kinase signaling. Mol Biol Rep. 2014 doi: 10.1007/s11033-014-3046-4. [DOI] [PubMed] [Google Scholar] · DOI
  104. [108]Neuwirt H, Puhr M, Santer FR, et al. Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol. 2009;174:1921–1930. doi: 10.2353/ajpath.2009.080751. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Kazi, J. U., Kabir, N. N., Flores-Morales, A., & Rönnstrand, L.
Venue
Cellular and Molecular Life Sciences
Publisher
Springer Science and Business Media LLC
Published
2014-04-05
Volume
71
Issue
17
Pages
3297-3310
ISSN
  • 1420-682X
  • 1420-9071
DOI
10.1007/s00018-014-1619-y
Cited by
92
References
4
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review